###### 

Changes in eGFR at week 48 and tubular laboratory abnormalities by baseline eGFR

  S-PI Study Arm                                                     STB                   STB                     PI+RTV               PI+RTV
  ------------------------------------------------------------------ --------------------- ----------------------- -------------------- ---------------------
  Baseline eGFR (mL/min) category                                    \<90 (n=40)           ≥90 (n=253)             \<90 (n=27)          ≥90 (n=113)
  Changes from baseline at week 48: eGFR (mL/min), median (IQR)      −3.8 (−8.1 to 1.2)    −8.9 (−16.9 to 0.4)     −0.2 (−4.5 to 5.0)   0.5 (−9.1 to 7.3)
  Hypophosphatemia[\*](#TF0001_19807){ref-type="table-fn"}           0                     0.4% (1)                0                    0
  Normoglycemic glycosuria[\*](#TF0001_19807){ref-type="table-fn"}   0                     0                       0                    0
  Proteinuria[\*](#TF0001_19807){ref-type="table-fn"}                5.0% (2)              9.5% (24)               11.1% (3)            7.1% (8)
  **S-NNRTI Study Arm**                                              **STB**               **STB**                 **PI+RTV**           **PI+RTV**
  Baseline eGFR (mL/min) category                                    \<90 (n=43)           ≥90 (n=248)             \<90 (n=20)          ≥90 (n=123)
  Changes from baseline at week 48: eGFR (mL/min), median (IQR)      −8.0 (−11.6 to 0.9)   −12.6 (−21.2 to −6.3)   7.4 (1.9 to 14.4)    −1.7 (−10.9 to 5.8)
  Hypophosphatemia[\*](#TF0001_19807){ref-type="table-fn"}           4.7% (2)              0                       0                    1.6% (2)
  Normoglycemic glycosuria[\*](#TF0001_19807){ref-type="table-fn"}   2.3% (1)              1.2% (3)                0                    0
  Proteinuria[\*](#TF0001_19807){ref-type="table-fn"}                9.3% (4)              6.9% (17)               10% (2)              4.9% (6)
                                                                                                                                        

≥1-grade increase from baseline observed at two consecutive post-baseline visits (within 30 days after last dose date).
